In liver, the 470-residue bifunctional enzyme 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase (PFK-2/FBPase-2) catalyses the synthesis and degradation of fructose 2,6-bisphosphate, a potent stimulator of glycolysis. In rat hepatoma (HTC) cells, this enzyme has kinetic, antigenic, and regulatory properties, such as insensitivity to cyclic AMP-dependent protein kinase and lack of associated FBPase-2 activity, that differ from those in liver. To compare the sequence of the HTC enzyme with that of the liver enzyme, we have cloned the corresponding fully-coding cDNA from HTC cells. This cDNA predicts a protein of 448 residues in which the first 32 residues of liver PFK-2/FBPase-2 including the cyclic AMP target sequence have been replaced by a unique N-terminal decapeptide. The rest of the protein is identical with the liver enzyme. An Nterminally truncated recombinant peptide of 380 residues containing the PFK-2 and FBPase-2 domains was expressed in Escherichia coli as a beta-galac...
INTRODUCTION
As shown by Warburg 60 years ago, a high aerobic glycolysis is a typical feature of the transformed cell phenotype. No fully satisfactory explanation for this phenomenon has been provided (Weinhouse, 1976) . The most potent stimulator of glycolysis is fructose 2,6-bisphosphate, an ubiquitous allosteric activator of 6-phosphofructo-l-kinase (reviewed by . The synthesis of fructose 2,6-bisphosphate is catalysed by 6-phosphofructo-2-kinase (PFK-2) and its degradation by fructose-2,6-bisphosphatase (FBPase-2). In liver, these two enzyme activities are borne by each subunit (54470 Da) of a homodimeric protein which is phosphorylated by cyclic AMP-dependent protein kinase. Cyclic AMP thereby inactivates PFK-2 and activates FBPase-2. In several tissues, fructose 2,6-bisphosphate concentration is controlled. by growth factors, tumour promoters, and oncogene products (reviewed by . Rat hepatoma cells of the dedifferentiated line HTC have a high glycolytic rate (Schamhart et al., 1979) and their fructose 2,6-bisphosphate regulation differs from that in normal liver (Loiseau et al., 1985) . Thus, perturbations of fructose 2,6-bisphosphate control or expression of an abnormal PFK-2/FBPase-2 might contribute to the changes in glucose metabolism seen in transformed cells.
As one approach to this problem, we have compared the PFK-2/FBPase-2 purified from HTC cells with that from rat liver (Loiseau et al., 1988) . HTC cell PFK-2 has kinetic and antigenic properties different from those in liver and it is not a substrate of cyclic AMP-dependent protein kinase. Moreover, PFK-2 purified from HTC cells does not contain detectable FBPase-2 activity. Because no sequence information on the HTC enzyme was available, we have now cloned the cDNA corresponding to the HTC cell enzyme and have compared its sequence with that of the rat liver cDNA (Darville et al., 1987) that encodes the full-length (470 amino acids) bifunctional PFK-2/FBPase-2 polypeptide. Besides low concentrations of a mRNA for the liver-type PFK-2/FBPase-2, HTC cells contained a mRNA encoding a PFK-2 devoid of the cyclic AMP-responsive phosphorylation site. When expressed in E. coli, this mRNA was translated into a protein that had several of the properties of HTC cell PFK-2.
Vol. 264
Abbreviations used: bp, base pair(s); DTT, dithiothreitol; FBPase-2, fructose-2,6-bisphosphatase (EC 3.1.3.46); HTC, hepatoma tissue culture; IPTG, isopropyl-,/-D-thiogalactopyranoside; LDH, lactate dehydrogenase (EC 1.1.2.3.); PEG, poly(ethylene glycol); PFK-2, 6-phosphofructo-2-kinase (EC 2.7.1.105); SSC, standard saline citrate; PAGE, polyacrylamide-gel electrophoresis.
I To whom correspondence and reprint requests should be addressed.
151
MATERIALS AND METHODS Cells HTC cells (clone 4.7 isolated by Dr. M. Marchand) were grown in suspension and the effect of dexamethasone was studied in serum-free medium as described (Loiseau et al., 1985) . Cells were centrifuged at 0°C (2000 g, 2 min), washed twice in phosphate-buffered saline (0.15 M-NaCl, 2.5 mM-KCl, 8 mM-Na2HPO4 and 1.5 mM-KH2PO4 pH 7.45) and kept at -80 'C. To prepare cytosol, the cell pellets were resuspended (3 vol./g) in ice-cold buffer (50 mM-Hepes, 0.1 M-KCI and 15 mm-2-mercaptoethanol, pH 7.2) and disrupted with an Ultraturrax homogenizer (4 x 15 s). The homogenate was centrifuged at 4 'C in a Sorvall SS-34 rotor (10000 g, 10 min), then in a 50 Ti Beckman rotor (105 000 g, 1 h). The supernatant (cytosol) was stored at -80 'C.
Purification and hybridization of nucleic acids
Total RNA was isolated from HTC cells by the LiCl/urea method (Auffray & Rougeon, 1980) . Poly(A)-rich RNA (2-4 % of total RNA) was purified by two cycles of oligo(dT)-cellulose (type 7 from Pharmacia) chromatography (Aviv & Leder, 1972) . Dot blot hybridization of total RNA was performed as described using a chicken /8-actin cDNA probe as a control (Crepin et al., 1988) . Phage DNA was prepared as described (Maniatis et al., 1982) using the plate lysate method.
Construction and screening of the HTC cell cDNA library in Igtll Poly(A)-rich RNA from HTC cells was tested for the mRNA of interest by dot blot hybridization to the rat liver PFK-2 cDNA probes RL2K-22c2 and RL2K-8. cDNA was synthesized with an Amersham kit that combines oligo(dT) priming and random priming of the first strand with 13-mer oligonucleotides (gift of Dr. J. N. Octave). After methylation and ligation of EcoRI linkers, the cDNA products were cut with EcoRI, purified by gel filtration (Bio-Gel A-SOm; Bio-Rad) and ligated (Young & Davis, 1983a) in Agtl 1 (Protoclone Agt Il system; Promega). DNA was packaged in vitro (Gigapack; Genofit) and plated on E. coli Y1090 (Young & Davis, 1983b (Maniatis et al., 1982) at 60 "C for 4 h, hybridization was carried out for at least 12 h at 60 "C in 25 mM-sodium phosphate buffer, pH 7.0, containing 3.5 x SSC, 1 x Denhardt's solution, 0.5 % SDS, 2 mM-EDTA (pH 8) and 100 ,ug of heat-denatured herring sperm DNA/ml. The cDNA probes RL2K-8 and RL2K-22c2 were multiprime-labelled (Amersham) with [a-32P]dCTP (3000 Ci/mmol; Amersham) and added at 0.5 x 106 c.p.m./ml. Filters were washed twice in 2 x SSC/0.2 0 SDS for 30 min at 50 "C. Plaques which remained positive after three successive screenings were purified and analysed by restriction enzyme (Promega or Boehringer) mapping.
DNA sequencing
Following restriction with PstI, EcoRI, RsaI and BglII, cDNA fragments were purified on agarose gels (Lizardi et al., 1984) and subcloned into the single-stranded Ml 3 mp8 or/and mp9 bacteriophages (Messing et al., 1977) . The E. coli JM1I1 host strain (Yanisch-Perron et al., 1985) was transformed with the phages by the calcium chloride method (Maniatis et al., 1982) . The nucleotide sequence of cDNA subclones was determined by the dideoxy chain termination method (Sanger et al., 1977) Agtl 1 recombinant lysogens in Y1089 were prepared as described (Huynh et al., 1985) . L-broth medium (200 ml) containing 50 jug of ampicillin/ml was inoculated with a 6-ml overnight culture of the lysogens of interest and grown at 32 "C until the A600 reached 0.6-0.8. The phages were heat-induced at 45 "C for 20 min. Production of the fusion protein was induced at 38 "C with 2 mM-IPTG. After shaking the cultures for I h, cells were harvested by centrifugation at 25 "C (8000 g, 10 min) and quickly suspended in a volume of cold lysis buffer (50 mM-Hepes-KOH, pH 7.5, 100 mM-KCl, 1 mmpotassium phosphate and 0.1 mm phenylmethanesulphonyl fluoride) equal to 1/50 of the culture volume. The suspension was frozen in 1 ml aliquots on solid CO2 and allowed to thaw on ice for 3 h. Insoluble material was removed by centrifugation at 4 "C (10000 g, 10 min) and the supernatant was stored at -80 "C. PFK-2 was partially purified by poly(ethylene glycol) (PEG) precipitation followed by Blue-Sepharose chromatography as described (Loiseau et al., 1988) . Peptide synthesis A decapeptide GELTQTRLQK corresponding to the N-terminus of liver PFK-2 (to raise a L-antibody) and a nonapeptide EEKASKRTA corresponding to the putative N-terminus of HTC PFK-2 (to raise a M-antibody) were prepared by solid phase on a Beckman 990B automatic peptide synthesizer. Merrifield's solid phase method was applied. t-Butyloxycarbonyl-(N6-2-chlorobenzyl)lysine and t-butyloxycarbonylalanine resins (-0.3 (Steward & Young, 1984 The synthetic peptides (1 mg) were coupled with glutaraldehyde, at room temperature in the dark for at least 12 h, to 2 mg of keyhole limpet haemocyanin (Calbiochem) using the procedure of Avrameas & Ternyck (1969) . Rabbits (New Zealand White) were immunized by multiple intradermal injections on day 0 with the peptide-haemocyanin in complete Freund's adjuvant (1:1) and on day 15 and every fortnight thereafter with 660 ,g of peptide-haemocyanin in incomplete Freund's adjuvant. Rabbits were bled every other week beginning on day 28. y-Globulins were precipitated from antisera with 45 % (NH4)2S04, dissolved in one-third of the initial volume in phosphatebuffered saline and dialysed three times against the same buffer over a 16 h period at 4 'C. Their purity was checked by SDS/PAGE and they were stored at -20 'C. By e.l.i.s.a. (Coutelier et al., 1986) , the L-and Mantibodies recognized specifically their cognate synthetic antigen at dilutions up to 1: 105. These antibodies did not immunoprecipitate (Crepin et al., 1988) PFK-2 activity from liver or HTC cells, as if they could not interact with the native enzyme. However, they were active in immunoblots (see the text). Protein electrophoresis and immunoblotting Proteins (up to 200, ug) were electrophoretically separated in a SDS/PAGE (8 %) gel according to Laemmli (1970) . After the run, the gel was equilibrated in transfer buffer (25 mM-Tris base, 192 mM-glycine, 20 % methanol) and electroblotted onto an Immobilon PVDF membrane (Millipore) at 4 'C overnight at 50 V (150 mA) (Towbin et al., 1979) . Subsequent handling of the membrane followed the manufacturer's instructions. (1982) , in the presence of 20 mM-Tes (pH 7.5), 100 mM-KCI, 1 mM-dithioerythritol, 1 mM-potassium phosphate, 5 mM-MgCl2, 1 mM-sn-glycerol 3-phosphate and 1 mM Mg-GTP at 30 IC for 30 s in 100 #s1. The reaction was stopped by adding 4 gul of cold 100 % trichloroacetic acid. After 10 min on ice, the incubation was neutralized by 20 #l of 2 M-Tris base and analysed by SDS/PAGE.
Assay of enzyme activities PFK-2 activity was measured at pH 8.5 as described (Bartrons et al., 1983) or at pH 7.1 in 50 mM-Hepes, 0.1 M-KCI, 20 mM-KF, 1 mM-DTT, 2 mM-fructose 6-phosphate, 5 mM-Mg-ATP and 5 mM-potassium phosphate. FBPase-2 activity was measured by the production of [32P]P, from fructose 2,6-[2-32P]bisphosphate.
The reaction was carried out at 30°C in 500 ,ul containing 20 mM-Tes, pH 7.5, 100 mM-KCI, 5 mM-MgCl2, 1 mM-DTT, 1 mM-sn-glycerol 3-phosphate, 1 mM-potassium phosphate, 1 mM-Mg-GTP and 10 gM-fructose 2,6-[2-32P]-bisphosphate (50000 c.p.m./assay). The reaction was stopped by addition of 100 ,1 of 1 M-NaOH, and [32P]P, was separated from the substrate as described (Loiseau et al., 1988) . Thermolysin digestion of PFK-2/FBPase-2 Thermolysin (Boehringer) solutions (0.01-1 mg/ml) were freshly prepared in buffer A (20 mM-Hepes, pH 7.5, 50 mM-KCl, 5 mM-MgCl2, 2 mM-EDTA, 15 mM-2-mercaptoethanol and I mM-potassium phosphate) and clarified by centrifugation. PFK-2/FBPase-2 (5-20 % PEG fraction in buffer A) was incubated for 15 min at 30°C with thermolysin (0-100 ,ug/ml) and 2 mM-CaCl2. The digestion was stopped with 10 mM-EGTA and 30 ,ul aliquots were assayed for PFK-2 activity at pH 7.1 and for FBPase-2 activity.
Other methods
Protein was determined (Bradford, 1976) with bovine serum albumin as a standard. cDNA probes were labelled with [a-32P]dCTP (3000 Ci/mmol) using the Amersham Multiprime DNA labelling system. The BCL-2 (Crepin et al., 1988 ) and IRL-6 (Darville et al., 1987 ) antisera were prepared as described.
RESULTS
Cloning of 6-phosphofructo-2-kinase cDNA from HTC cells predicts a novel protein A cDNA library in Agtl 1 (14 x 106 clones, 85 % of which were recombinants) was prepared from HTC cell poly(A)-rich RNA. We did not try to identify positive clones with antibodies because none of our antisera raised against native chicken liver (BCL-2) or denatured rat liver (IRL-6) PFK-2/FBPase-2 gave positive signals with PFK-2, when immunoblotting cytosolic proteins from HTC cells. We therefore screened the library with two rat liver cDNA probes (Darville et al., 1987) , one corresponding to the 5'-and one to the 3'-moieties of PFK-2/FBPase-2 (Fig. 1) . Probe 22c2 extends from the 5'-end to the EcoRI site of the fully-coding cDNA RL2K-22c; it corresponds to the first 446 bp which include the sequence for the first 90 amino acids of the liver bifunctional enzyme. Probe RL2K-8 is an incomplete cDNA of 1086 bp that includes the sequence for amino acids 167-470, i.e. the C-terminus of that same enzyme. In dot blot hybridization assays with total RNA from HTC cells, these probes gave signals that persisted under high stringency conditions (0.2 x SSC buffer, 65°C). By screening 5.4 x 106 recombinants, 21 clones were detected with probe 22c2. Restriction with EcoRI showed that all these clones contained a fragment the length of which (1.4 kb) was equal to that of the 3' EcoRI fragment of cDNA RL2K-22c. The clones contained a Fig. 2 . Note that the amino acid sequence is the same in all the clones, except for the filled area of clone RL2K-5c (identical to clones HTC-20, -25 and -34) which corresponds to amino acids that are specific to these clones. Sequences were not systematically determined on both strands when they were confirmatory of sequences obtained independently (Darville et al., 1987; Crepin et al., 1989) on identical clones. B, BglII; D, DdeI; E, EcoRI; P, PstI; R, RsaI; S, Sau3A. second fragment which was about 300 bp long in nine of them (among which clones HTC-20, -25 and -34) and about 450 bp long in twelve of them (among which clones HTC-22 and -41). Interestingly, the 5' EcoRI fragment of RL2K-22c is 446 bp long. Two more clones of 1.4 kb were detected with probe RL2K-8. Restriction of clone HTC-15 with RsaI, Bglll, PstI and Hinfl yielded a map identical to that of the 1.4 kb long 3' EcoRI fragment of the rat liver cDNA RL2K-22c.
This survey therefore suggested that HTC cell poly(A)-rich RNA yielded two cDNA populations, one corresponding to a mRNA similar or identical to that of normal liver, and one corresponding to an incomplete copy of this mRNA or to a mRNA that differs from it at the 5' end. The sequence of clones HTC-22 and -41 was identical with that of the rat liver RL2K-22c cDNA.
Clones HTC-15 and -35 were identical; they are truncated versions of RL2K-22c, encoding residues 91-470 of PFK-2/FBPase 2. Sequencing of clones HTC-20, -25 and -34 showed that they were identical but corresponded to a different type of PFK-2/FBPase-2 mRNA. Indeed, their sequence differed from the liver-type at the 5' end such that the first 32 amino acids of the liver enzyme (Darville et al., 1987) are replaced by a unique sequence (a data bank search of similarity with known proteins was negative) of 10 amino acids (Fig. 2) . Upstream from this sequence there is an open reading frame containing another AUG. However, this second AUG is within a nucleotide sequence incompatible with initiation of translation (Kozak, 1987) . Our current work on a PFK-2/FBPase-2 gene encoding this mRNA, and localization ofthe transcription initiation site by SI nuclease mapping and primer extension suggest that translation does not start further upstream than indicated in Fig. 2 . The predicted molecular mass of the HTC cell enzyme is therefore 52011 Da, as compared to 54470 Da for the liver enzyme. We have now found ) that this HTCtype mRNA is present at low levels in normal liver and corresponds to the cDNA RL2K-5c cloned earlier (Darville et al., 1987 ) from rat liver but not characterized at the time.
The putative protein encoded by the HTC-type mRNA does not possess the serine residue phosphorylated by cyclic AMP-dependent protein kinase in the liver enzyme (Ser-32). This provides an explanation for the lack of regulation of the HTC cell enzyme by cyclic AMP. The rest of the protein is identical to the liver-type enzyme including the PFK-2 and FBPase-2 catalytic domains and consensus sequences for nucleotide binding folds. The PFK-2 domain includes Cys-160, -183 and -198 and the FBPase-2 domain includes His-258 (Lively et al., 1988) (Fig. 2) . To investigate the actual properties of this enzyme, we expressed in E. coli the protein corresponding to the peculiar PFK-2/FBPase-2 mRNA cloned from HTC cells. The enzymic detection of this protein was facilitated by the fact that, unlike eukaryotes, prokaryotes have no detectable endogenous PFK-2/FBPase-2 activity . Expression of the cloned protein in E. coli
Unlike for the liver-type full cDNA clones, the nontranslated leader sequence is an open-reading frame in the fully-coding HTC-type cDNA clones (Fig. 2) . Thus, we attempted to express in Agtl 1-containing E. coli the whole polypeptide encoded by the HTC-type cDNA, as a 8-galactosidase fusion protein. We first determined which ones of our fully-coding HTC-type Agtl 1 clones found to be positive by cDNA hybridization did express immunodetectable PFK-2. The phages were plated on the E. coli Y1090 strain at 42 'C. A non-recombinant A phage was used as a negative control. As positive control, we used clone RL2K-8, known to express immunodetectable PFK-2 under those conditions (Darville et al., 1987) . We also included the incomplete clones HTC-15 and -35 with the hope they were in-frame and in the right orientation. After induction with IPTG and transfer on nitrocellulose filters, the plaques were screened with the This clone differs from normal rat liver PFK-2/FBPase-2 in terms of 5' nucleotide sequence and corresponding N-terminal peptide sequence upstream from Ser-33 (asterisk). Numbers on the right refer to amino acids numbered as they occur in normal liver PFK-2/FBPase-2, starting here at Ser-33. The putative translation initiation site is in brackets. Between parentheses is the open reading frame which, in the expression vector described, links PFK-2/FBPase-2 to fl-galactosidase. The critical cysteines of the PFK-2 domain and the critical histidine of the FBPase-2 domain are circled. The nucleotide binding motifs are indicated by dotted lines. Putative sites for phosphorylation by protein kinase C (Ser-28) and by tyrosine-specific protein kinase (Tyr-358) are underlined twice, within the consensus underlined once. Arrows show where the indicated clones begin. Table 1 . 6-Phosphofructo-2-kinase (PFK-2) and fructose-2,6-bisphosphatase (FBPase-2) activities in lysates from E. coli Agtl1 recombinants and of purified enzymes PFK-2 was assayed at pH 8.5. Data are means + S.E.M. for the number of experiments given in parentheses. n.d., not detectable; n.s., E. coli phosphatase activity (34+10 ,uunits/mg of protein, n = 4) considered as nonspecific because non-recombinant lysates could not be labelled with radioactive fructose 2,6-bisphosphate (see Fig. 3 with the fully-coding clones, except HTC-20 which was presumably in the reverse orientation.
To produce preparative amounts of fusion proteins, strain Y1089 was lysogenized with clones HTC-25 and -34 which are identical and encode a full-length HTC-type enzyme, and with clone HTC-35 which encodes a Nterminally truncated protein sequence common to the HTC-type and liver-type enzymes. A non-recombinant A phage was used as non-expressing control. Lysogenic cultures were induced with IPTG and the lysates were assayed for PFK-2 and FBPase-2 activities. No inclusion bodies were seen by phase contrast microscopy prior to lysis. As shown in Table 1 , both activities were expressed by the fully-coding clones HTC-25 and -34. In contrast to the situation in HTC cells, when PFK-2 was purified from these lysates, FBPase-2 copurified with this enzyme. This is consistent with the integrity of the two catalytic domains of the bifunctional enzyme in the polypeptide sequence predicted from the nucleotide sequence of these clones (Fig. 2) . The PFK-2 activity in lysates from clone HTC-25 was immunoprecipitable by BCL-2 antiserum (not shown), as is the case for the liver (Crepin et al., 1988) and HTC cell (Loiseau et al., 1988) Table 1 for the fully coding clones is reminiscent of that described for the muscle bifunctional enzyme, which is 5-10, as compared to 0.3 for liver (Table 1 and . We therefore examined whether the FBPase-2 of the recombinant protein was, like muscle FBPase-2, 5-fold less sensitive to inhibition by fructose 6-phosphate than liver FBPase-2 (see (Fig. 3) , as expected from the predicted length of the fl-galactosidase fusion protein. In contrast, the protein labelled in lysates from the fullycoding clones HTC-25 and -34 had an Mr of about 53 000 and was much more radioactive than in clone HTC-35 (Fig. 3) . Densitometry showed that the relative intensity (1:4.4:7.8) of labelling of the lysates from clones HTC-35, -25 and -34 reflected their relative FBPase-2 activity (Table 1 ). This experiment suggests that the bisphosphatase domain of the fully-coding clones is borne by a protein with a M, similar to that expected from the sequence of the HTC-type PFK-2/FBPase-2 polypeptide (52011 Da), and that this protein has separated from /8-galactosidase. This interpretation was confirmed by successive immunoblotting with a monoclonal anti-,/-galactosidase antibody and with the anti-PFK-2 serum IRL-6. The incomplete clone HTC-35 expressed a protein of Mr about 155 000 (Fig. 4 , arrow a) that was detected with both antibodies. In contrast, two proteins were detected in the lysates from the fullycoding clones, one of Mr 116000 revealed by the anti-,fgalactosidase antibody (Fig. 4b) and one of Mr 53000 revealed by the anti-PFK-2 antibody (Fig. 4c) .
Thus, Agtl 1 recombined with a clone encoding amino acids 91-470, which are common to the liver-type and HTC-type enzyme, expressed a ,-galactosidase fusion protein containing the PFK-2 and FBPase-2 domains but expressing much less of the corresponding activities (Table 1) . On the other hand, Agtl 1 recombined with a fully-coding HTC-type clone expressed a protein cleaved from ,-galactosidase and endowed with both the PFK-2 and FBPase-2 activities.
Comparison of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase expressed in E. coli with the HTC cell enzyme HTC cell PFK-2 is not inhibited by sn-glycerol 3-phosphate, in contrast to the liver enzyme, and it is more sensitive than liver PFK-2 to inhibition by citrate, like the muscle enzyme (Loiseau et al., 1988) . We therefore determined whether these peculiar kinetic properties of HTC cell PFK-2 were retained following expression in E.
coli and cleavage from fl-galactosidase. This was the case (Fig. 5) . Despite these similarities, one difference between 1989 this recombinant PFK-2/FBPase-2 and the HTC cell enzyme was the absence from the latter of associated FBPase-2 activity and of specific labelling with fructose 2,6-bisphosphate (Loiseau et al., 1988) . We speculated that, in HTC cells, the enzyme has been cleaved such that its FBPase-2 domain was lost. This was ruled out by immunoblotting with the IRL-6 antibody, which indicated that the apparent Mr of PFK-2 partially purified from HTC cells was not shorter than that expected from the cloning data. Actually a minor (Mr 58000) and a major (Mr 56000) band were detected by this technique (Table 2) . This is consistent with expression of the L-type and of the shorter HTC-type isoenzyme in these cells (see above). The discrepancy between these Mr values and those predicted from the cloning data (54470 and 52011 Da respectively) is discussed below. Thus, there is no evidence that the HTC-type enzyme has lost the FBPase-2 domain in HTC cells. However, interaction between distinct portions of this protein could mask latent FBPase-2 activity. El-Maghrabi et al. (1984) have indeed shown that the N-terminal portion of the livertype enzyme inhibits FBPase-2 activity, since removal by limited thermolysin digestion of 200-odd N-terminal amino acids abolished PFK-2 activity but doubled FBPase-2 activity. The N-terminal amino acids of the HTC-type enzyme, which differ from those in the livertype enzyme, might therefore inhibit FBPase-2 activity. The E. coli-expressed protein would exhibit FBPase-2 activity because the cleavage from ,-galactosidase removes these inhibitory N-terminal amino acids ofPFK-2. If these hypotheses were true, then limited thermolysin digestion of the enzyme in HTC cell extracts should reveal FBPase-2 activity. This treatment was therefore applied and the results compared with those obtained with the liver extracts. As expected, increasing concentrations of thermolysin abolished the PFK-2 activity and doubled the FBPase-2 activity of the bifunctional enzyme in liver extracts. However, at concentrations of thermolysin that abolished PFK-2 activity in HTC cell extracts, there was no stimulation of basal FBPase-2 activity (not shown). This basal thermolysin-insensitive FBPase-2 activity has kinetic properties quite different from those of liver FBPase-2 and it has been ascribed to a different enzyme (Loiseau et al., 1988) . If, indeed, cleavage from ,-galactosidase did not remove the predicted N-terminus of recombinant PFK-2, then antibodies raised against the N-terminus of the HTC-type PFK-2 should recognize the cleaved enzyme in recombinant E. coli lysates. A nonapeptide corresponding to those N-terminal amino acids (excluding the initial methionine) of the HTC-type enzyme which differ from the L-type enzyme (see Fig. 2 ) was therefore synthesized. A decapeptide corresponding to N-terminal amino acids that are unique to the L-type enzyme was also synthesized. These synthetic peptides were used to raise the specific M-and L-antibodies. When immunoblotting PFK-2 purified from rat liver, the Mantibody revealed a very faint band at Mr 53000 while the L-antibody revealed a major band at Mr 55000 (Table 2) . This is consistent with our identification in rat liver of the mRNA for the M-and L-isoenzymes of PFK-2. When PFK-2 purified from HTC-25 E. coli lysates was immunoblotted with these antibodies, no signal was seen with the L-antibody, as expected, while a band of Table 2 . Subunit Mr of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase
The subunit molecular masses are those predicted from the amino acid sequences or the cloning data (*). The subunit Mr values (t, t) were obtained as follows: proteins from liver, HTC cells and recombinant E. coli lysates from clones HTC-25 and -34 were labelled with fructose 2,6-[2-32P]bisphosphate before SDS/8 %-polyacrylamide gel electrophoresis (t); the same samples were also immunoblotted with the three anti-PFK-2 antibodies (t). The Mr 53000 was seen with the M-antibody (Table 2 ). This experiment shows that the predicted N-terminus of the HTC-type enzyme is indeed retained in the recombinant protein following cleavage from /1-galactosidase and it confirms the size of this protein (Mr 53000) already determined by labelling with fructose 2,6-bisphosphate ( Fig. 3 ) and by immunoblot with the IRL-6 antibody (Fig. 4) . As said above, the latter antibody identified in HTC cells a PFK-2 of apparent Mr greater than in E. coli lysates. This difference was now confirmed by immunoblotting PFK-2 purified from HTC cells, with the M-and L-antibodies. The M-antibody revealed a major band at Mr 56000 and the L-antibody revealed a minor band at Mr 58000 (Table 2) . We conclude from these experiments that both in HTC cells and in E. coli lysates the HTC-type enzyme contains the N-terminus as well as the FBPase-2 domain, as predicted from the cloning data. However, by SDS/PAGE, the migration of the protein extracted from HTC cells is slower than that expressed in E. coli. This might result from a covalent modification of the HTC protein which would also result in loss of FBPase-2 activity. This interpretation is supported by the fact that the L-isoenzyme, albeit expressed at low levels in HTC cells, does not contribute FBPase-2 activity either. Now, we observe that the apparent Mr of this L-isoenzyme in HTC cells is also about 3000 greater than in liver. Thus, the covalent modification postulated for the M- isoenzyme in HTC cells could also take place on the Lisoenzyme in these cells, as expected from their sharing an identical sequence of 438 amino acids.
Occurrence of two mRNAs for 6-phosphofructo-2-kinase in HTC cells and lack of induction by dexamethasone Our cloning data suggest that HTC cells contain not only a peculiar PFK-2 mRNA but also the normal liver PFK-2/FBPase-2 mRNA. To evaluate their relative concentration, total RNA from HTC cells was dotted on nitrocellulose filters and hybridized with three mutually exclusive cDNA probes (Fig. 1) . These probes were 5c2-DdeI which is specific for the HTC-type enzyme, 22c2-Sau3A which is specific for the liver enzyme, and HTC-15 or RL2K-8 which are common to both forms of the enzyme.
Hybridization signals were obtained with all these probes. 
DISCUSSION
We have shown here that HTC cells contain two mRNAs for PFK-2/FBPase-2, one present at low concentration which codes for the bifunctional enzyme found in normal liver, and one present at higher concentration which codes for a distinct protein. This protein lacks the cyclic AMP-dependent phosphorylation site at the N-terminus, as expected from the properties of the HTCtype enzyme, and it contains PFK-2 and FBPase-2 domains identical to those of the liver enzyme. Hybridization experiments with cDNA probes now indicate that this novel protein could correspond to the muscle isoenzyme of PFK-2/FBPase-2. Consistent with this hypothesis, we have shown here that, when this putative isoenzyme is expressed in E. coli, it displays kinetic properties of PFK-2 and of FBPase-2 that resemble those of the muscle rather than the liver enzyme. In that respect, the unique N-terminus of the cloned HTC-type enzyme exerts on these two activities a control similar to that observed for the fully phosphorylated liver enzyme, namely low PFK-2 and high FBPase-2 activities. This N-terminus contains a sequence Ser-Xaa-Arg (Fig. 2) that could serve as a target for phosphorylation by protein kinase C (Woodget et al., 1986) . Phorbol esters stimulate PFK-2 activity in fibroblasts (Bosca et al., 1985) . However, HTC cell PFK-2 activity remained unchanged following incubation of the cells with phorbol myristate acetate under the same conditions (not shown). Another feature that distinguishes the behaviour of this enzyme in HTC cells and liver is the mechanism by which it is induced by glucocorticoids. While Colosia et al. (1988) have reported that the concentration of mRNA for PFK-2/FBPase-2 increases in the liver of adrenalectomized rats treated with dexamethasone, we found no change in mRNA concentration, despite increased PFK-2 activity, following incubation of HTC cells with dexamethasone.
A recombinant clone containing a truncated cDNA (HTC-35) expressed a hybrid polypeptide consisting of ,8-galactosidase fused to a sequence common to the HTC 1989 and liver enzyme (residues 91-470) and known to contain the PFK-2 and FBPase-2 domains. These domains were identified by anti-PFK-2 antibodies and by labelling of the FBPase-2 catalytic site. Still, the PFK-2 activity was barely detectable. One reason might be the absence from this clone of the nucleotide binding motif, i.e. residues 48-54 (Fig. 2) . The FBPase-2 domain was poorly labelled, consistent with the low activity detected. Since the liver enzyme is a homodimer, the low FBPase-2 activity of the fusion protein could result from failure of the enzyme to dimerize in HTC-35 lysates. This interpretation seems unlikely because Tauler et al. (1988) have shown that the FBPase-2 domain of the liver enzyme can be labelled with fructose 2,6-bisphosphate and can be catalytically active in monomeric form when it is separated from the first 218 amino acids. Whether or not dimerization occurs in E. coli expressing the HTC-35 truncated clone, it is probable that ,-galactosidase hinders the PFK-2/FBPase-2 activities within the fusion protein. This hypothesis is consistent with the behaviour of the recombinant protein expressed by the fully-coding clones HTC-25 and -34. This protein became active as a PFK-2/FBPase-2 bifunctional enzyme following cleavage from ,3-galactosidase. The mechanism of this cleavage is unknown. In any case, our data show that proper folding of this complex protein can occur in E. coli lysates. This opens interesting perspectives for studying structure-function relationships by site-directed mutagenesis.
One property by which the recombinant protein differed from the HTC cell enzyme was FBPase-2 activity. This activity was displayed by the recombinant protein as expected from the cDNA and derived amino acid sequence and it correlated with specific labelling of the protein by fructose 2,6-bisphosphate, a unique property of FBPase-2. By the latter criterion, as well as by immunoblot, the recombinant protein had a subunit Mr similar to that predicted from the deduced amino acid sequence. We failed in our attempts at performing direct N-terminal sequencing of the recombinant protein and of the HTC enzyme. However, antibodies against synthetic peptides corresponding to the putative N-terminal amino acids reacted with the enzyme from the two sources, showing that they contained these amino acids. We therefore speculate that, in HTC cells, the FBPase-2 domain of the protein remains silent because of subunit interactions that do not occur in E. coli or of posttranslational modification(s). Note in this context that PFK-2/FBPase-2 contains a motif Arg-Xaa-Xaa-AspXaa-Xaa-Xaa-Tyr (Fig. 2) for phosphorylation by tyrosine-specific protein kinase (Woodget et al., 1986) . This is a potential regulatory site. A covalent modification of His-258 such that it can no longer bind fructose 2,6-bisphosphate is another possibility. Such modification(s) would explain the up-shift displayed by the HTC enzyme in SDS gels when compared to the recombinant enzyme. Loss of PFK-2-associated FBPase-2 activity in HTC cells might result in a higher steady-state concentration of fructose 2,6-bisphosphate and higher glycolytic rate.
